1) Volume loss (the deflated look) Common areas: temples, midface, under-eye hollowness, around the mouth, jawline
What is the difference between single and dual agonist peptides? Single agonists like Semaglutide target only the GLP-1 receptor
Abstract Introduction Clinical trials have demonstrated greater glycemic control and weight loss with once-weekly (OW) semaglutide versus other anti-diabetes medications, including sodium-glucose co-transporter 2 inhibitors (SGLT2is) in adults with type 2 diabetes (T2D), yet real-world evidence is limited
It combines efficacy with convenience, eliminating the need for injections
Case Report #2 A 2026 case report documented a 33-year-old man who had been prescribed semaglutide at a weekly dose of 2.4 mg
Neuropeptides 2021 PMID: 33418449 Source: U.S